The (pro)renin receptor—or (P)RR—protein may play a significant role in lung cancer, specifically in predicting which patients with the disease are at higher risk of recurrence.
A study, led by Nachino Kimura, MD, of Kagawa University in Japan, examined if there were associations between (P)RR expression and clinical outcomes in non-small cell lung cancer (NSCLC).
“Accumulating evidence has shown that (P)RR is expressed in various human cancers. However, its clinical impact in lung carcinomas remains unclear,” the researchers said.
To evaluate (P)RR in NSCLC, the researchers reviewed and analyzed data from 913 patients who had their disease resected between 1999 and 2016. They constructed tissue microarrays and investigated (P)RR and β-catenin expression using immunohistochemistry.
The findings showed that (P)RR downregulation was related to high-grade tumors and higher risk of NSCLC recurrence in all patients. Furthermore, the nuclear expression of β-catenin was associated with a greater chance of disease recurrence in patients with (P)RR-positive tumors.
(P)RR downregulation was an independent predictor of disease recurrence, according to a multivariate analysis. However, (P)RR had no association with outcomes in patients with squamous cell carcinoma.
“(P)RR downregulation is associated with a higher risk of recurrence in lung adenocarcinomas, thereby characterizing a prognostic subset within high-grade tumors,” the researchers concluded.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.